

## ANTONIO PALUMBO, MD



### Personal Information

Date and place of birth April 14, 1956 - Torino, Italy  
Office Ematologia 1, AOU "Città della Salute e della Scienza"  
Address Via Genova 3, 10126, Torino Italy  
Phone +39 0116334260, +39 0116336107  
Email [appalumbo@yahoo.com](mailto:appalumbo@yahoo.com); [antonio.palumbo@unito.it](mailto:antonio.palumbo@unito.it)

### Education:

1989 Postgraduate training: Clinical Hematology, University of Modena, Modena, Italy  
1985 Postgraduate training: Clinical Oncology, University of Torino, Torino, Italy  
1982 Clinical residency, Internal Medicine, University of Torino, Italy  
1980 Medical School, University of Torino, Torino, Italy

### International Appointments

1994 Visiting Physician, MD Anderson, University of Texas, Houston, USA  
1985-1986 Research Associate, Wistar Institute, University of Pennsylvania, Philadelphia, USA  
1981-1984 Visiting Scientist, Wistar Institute, University of Pennsylvania, Philadelphia, USA

### Academic Appointments

2006 - to date Associate Professor of Clinical Hematology, University of Torino, Torino, Italy

### Administrative Appointments/Responsibilities

2006 - to date Director Onco-Hematology Clinical Trial Unit, University of Torino, Torino, Italy  
2006 - to date Director, Myeloma Unit, Department Hematology, University of Torino, Torino, Italy  
1989 - 2006 Clinical Associate, Division of Hematology, University of Torino, Torino, Italy

### Society Membership

- American Society of Hematology (ASH)
- American Society of Clinical Oncology (ASCO)
- European Society of Hematology (EHA)
- European Society for Medical Oncology (ESMO)
- Italian Society of Hematology (SIE)
- Italian Society of Experimental Hematology (SIES)

### Award

2014 Robert Kyle Life Time Achievement Award  
2014-2015 Thomson Reuters Highly Cited Researcher List: "world's most influential scientific minds"  
2015 Medal of Honor from the President of the Italian Republic Sergio Mattarella

### Scientific Acquisitions

- Cloning of the alpha-chain of the human "T-cell receptor". **Science** 1985;227:1044-1047
- Melphalan prednisone thalidomide for myeloma. **Lancet**. 2006;367:825-31
- Allografting and autografting for myeloma. **N Engl J Med**. 2007;356:1110-20
- Bortezomib melphalan prednisone for myeloma. **N Engl J Med**. 2008;359:906-17
- Treatment paradigm for multiple myeloma. **N Engl J Med**. 2011;364:1046-60
- Continuous lenalidomide treatment for myeloma. **N Engl J Med**. 2012;366:1759-69
- Autologous transplantation and maintenance for myeloma. **N Engl J Med**. 2014;371:895-905
- Carfilzomib lenalidomide dexamethasone for myeloma **N Engl J Med**. 2015;372:142-52
- Elotuzumab lenalidomide dexamethasone for myeloma **N Engl J Med**. 2015;373:621-31
- Anti CD38 MoAb Daratumumab for myeloma **N Engl J Med**. 2015;373(13):1207-19

### Publications

- More than 500 peer-reviewed scientific papers
- H index 78
- H index (since 2011) 63

## REFERENCES

1. Palumbo A, Anderson K. Multiple Myeloma. *N Engl J Med*. 2011;364(11):1046-60.
2. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *J Clin Oncol*. 2011;29(8):986-93.
3. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. *Blood*. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27.
4. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. *Blood*. 2011;117(11):3025-31.
5. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hájek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). *Blood*. 2011;118(17):4519-29.
6. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*. 2012 May 10;366(19):1759-69. Erratum in: *N Engl J Med*. 2012;367(3):285.
7. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedè P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantonio G, Boccadoro M, Corradini P, Palumbo A. *Blood*. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17. Erratum in: *Blood*. 2014 Jun 12;123(24):3843.
8. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedè P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. *Blood*. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16.
9. Palumbo A, Bringhen S, Kumar SK, Lupporelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncol*. 2014;15(3):333-42.
10. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *J Clin Oncol*. 2014;32(6):587-600.
11. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; the ASPIRE Investigators. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. *N Engl J Med*. 2014 Dec 6. [Epub ahead of print]
12. McCarthy PL, Palumbo A. Maintenance therapy for multiple myeloma. *Hematol Oncol Clin North Am*. 2014 Oct;28(5):839-59. doi: 10.1016/j.hoc.2014.06.006. Epub 2014 Jul 22.
13. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedè P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Autologous transplantation and maintenance therapy in multiple myeloma. *N Engl J Med*. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.

14. Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. *Blood*. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759.
15. Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *J Clin Oncol*. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023.
16. European perspective on multiple myeloma treatment strategies in 2014. Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. *Oncologist*. 2014 Aug;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. Epub 2014 Jul 25. Review. PMID: 25063227 Free PMC Article
17. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. *J Clin Oncol*. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. Epub 2014 Jan 13. Review.
18. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A, Bringhen S, Kumar SK, Lupporelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. *Lancet Oncol*. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
19. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A. *Blood*. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22.
20. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. *Blood*. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27.
21. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. *J Clin Oncol*. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
22. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. *J Clin Oncol*. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
23. How I treat fragile myeloma patients. Larocca A, Palumbo A. *Blood*. 2015 Nov 5;126(19):2179-85. doi: 10.1182/blood-2015-05-612960. Epub 2015 Aug 31. Review.
24. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedé P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. *Lancet Oncol*. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
25. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantonio G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. *Blood*. 2016 Jan 4. pii: blood-2015-08-662627. [Epub ahead of print]